The study led by the University of Melbourne revealed Kava could be an alternative treatment to pharmaceutical products for people who suffer from Generalised Anxiety Disorders (GAD).
Lead researcher, Dr Jerome Sarris from Department of Psychiatry at the University of Melbourne, said GAD is a complex condition that significantly affected people's day-to-day lives.
Existing medications have a modest clinical effect and new effective options were needed for patients with anxiety.
"Based on previous work we have recognised that plant based medicines may be a viable treatment for patients with chronic anxiety," he said.
The study also found that people's genetic differences (polymorphisms) of certain neurobiological mechanisms called GABA transporters, may modify their response to Kava.
"If this finding is replicated, it may pave the way for simple genetic tests to determine which people may be likely to have a beneficial anxiety-reducing effect from taking Kava," Sarris said.
During the eight-week study, 75 patients with clinically diagnosed GAD were given Kava or placebo, and anxiety levels were regularly assessed.
In participants diagnosed with moderate to severe GAD, Kava had an even greater effect in reducing anxiety. Following the completion of the controlled phase, 26 per cent of the Kava group were classified as in remission from their symptoms compared to six per cent of the placebo group.
Participants in the Kava group were given tablets twice per day consisting of water-soluble extracted Kava (peeled rootstock) for a total dose of 120mg of kavalactones for the first three-week controlled phase.
Kava was also well tolerated. Results showed no significant differences across the two groups for liver function which had previously been a concern for Kava's medicinal use.
The study was published in the Journal of Clinical Psychopharmacology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
